An online, open-access, cost comparison tool for presumptive tuberculosis testing using low complexity, automated, nucleic acid amplification tests (LCaNAAT) versus near point-of-care (NPOCs) molecular tests

2026-02-18 infectious diseases Title + abstract only

Show abstract

The world is far from achieving universal access to rapid tuberculosis (TB) diagnostics that align with World Health Organization (WHO) diagnostic standards. Although WHO-recommended molecular rapid diagnostics (mWRDs), including low-complexity automated nucleic acid amplification tests (LCaNAAT), have significantly improved TB detection, scale-up has been constrained by high capital, maintenance, and consumable costs. Recently, lower-cost, near-point-of-care nucleic acid amplification tests (NP...

An online, open-access, cost comparison tool for presumptive tuberculosis testing using low complexity, automated, nucleic acid amplification tests (LCaNAAT) versus near point-of-care (NPOCs) molecular tests

Predicted journal destinations